Liu Kangcheng, Chan Yau Kei, Peng Xia, Yuan Ruolan, Liao Min, Liang Jingwen, Tang Xiangbo, Xu Yi, Cai Yingjun, Li Qiangxiang, Wang Hua
Eye Center of Xiangya Hospital, Hunan Key Laboratory of Ophthalmology, Central South University, Changsha, China.
Department of Ophthalmology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Front Med (Lausanne). 2021 Nov 12;8:769132. doi: 10.3389/fmed.2021.769132. eCollection 2021.
To explore the therapeutic effect of a dietary supplement on dry eye with meibomian gland dysfunction (MGD). Sixty patients with MGD-related dry eye were included in this prospective and randomized, placebo-controlled study. All the subjects were treated with eye hot compress, artificial tears, and antibiotic ointment. After that, the patients received dietary supplementary or placebo daily for 12 weeks. The dry eye signs, function of MG, and visual quality of the patients were assessed at 4, 8, and 12 weeks after the treatment. Twelve weeks after the treatment, patients who received dietary supplement had a significantly better improvement of dry eye symptoms, in terms of ocular surface diseases index and tear breaking-up time (TBUT), than those who received placebo ( < 0.05). The functions of MG, in terms of meibum quality and MG exclusion and MG obstruction scores, were significantly improved in both dietary supplement and placebo groups ( < 0.05). Patients who received dietary supplement had a significantly better improvement in the MG structure, in terms of acinar diameter and acinar density, than those who received placebo ( < 0.05). The number of inflammatory cells near MG was significantly lower in the dietary supplement group when compared with the placebo group ( < 0.05). The objective visual quality was significantly improved in the dietary supplement group, but not in the placebo group ( < 0.05). The dietary supplement can effectively improve the symptoms and signs of MGD-related dry eye, reduce the inflammatory reaction of MG, restore the gland structure, and indirectly improve the visual quality.
探讨一种膳食补充剂对睑板腺功能障碍（MGD）相关干眼的治疗效果。本前瞻性随机安慰剂对照研究纳入了60例MGD相关干眼患者。所有受试者均接受眼部热敷、人工泪液和抗生素眼膏治疗。之后，患者每天接受膳食补充剂或安慰剂治疗12周。在治疗后4周、8周和12周评估患者的干眼体征、睑板腺功能和视觉质量。治疗12周后，接受膳食补充剂的患者在眼表疾病指数和泪膜破裂时间（TBUT）方面，干眼症状的改善明显优于接受安慰剂的患者（P<0.05）。在睑脂质量、睑板腺排出和睑板腺阻塞评分方面，膳食补充剂组和安慰剂组的睑板腺功能均有显著改善（P<0.05）。在腺泡直径和腺泡密度方面，接受膳食补充剂的患者睑板腺结构的改善明显优于接受安慰剂的患者（P<0.05）。与安慰剂组相比，膳食补充剂组睑板腺附近的炎症细胞数量显著减少（P<0.05）。膳食补充剂组的客观视觉质量显著改善，而安慰剂组则无改善（P<0.05）。该膳食补充剂可有效改善MGD相关干眼的症状和体征，减轻睑板腺的炎症反应，恢复腺体结构，并间接改善视觉质量。
